|Bid Price||GBX 136.30||Offer Price||GBX 136.60|
|Mid Price||-||Day Change||GBX +0.10 (0.07%)|
|Price Date||20 Oct 2017||Crown Rating|
|Shares Class||Inc.||Yield||0.46 %|
|Total Expense Ratio||0.00||Fund Size||230,014,700.00|
|Launch Date||22/05/2000||Standard Initial Charge (%)||0.00|
|Annual Management Charge (%)||0.75||Sector||IMA UK Equity Income|
|Min Investment (£)||1,000,000.00||Total Expense Ratio (%)||0.00|
|ISIN||GB00B76V7R15||Min TopUp (£)||100,000.00|
The fund's investment objective is to achieve capital growth. The fund will invest in healthcare, medical services and related products and companies on a world wide basis. Investment will be in directly held transferable securities. The fund may also invest in collective investment schemes, warrants and money market instruments.
John Joined Schroders in 2003.Investment career commenced in 1994.Currently Global Sector Specialist with responsibility for the healthcare sector and manager of the Schroder Medical Discovery Fund, as well as having primary research responsibility for Pan-European pharmaceuticals. Based in London John joined Schroders from AXA Investment Managers, where he had worked since 1998 in a global healthcare research role. He was voted top buy-side analyst for the pharmaceutical and healthcare sector in the Institutional Investor Pan European Equity survey in 2002.Before this, John worked at State Street Research & Management from 1997 as a fund manager / analyst.Earlier, John joined Hill Samuel Asset Management in 1994 as a graduate trainee, later becoming a junior fund manager for UK equities.Institute of Investment Management and Research (IIMR) qualified. Member of the CFA Society of the UK (CFA UK). PhD in Biochemistry & Physiology, from the University of Manchester. Degree in Biology from the University of Manchester.